Yuwen Zhu, PhD
Chief Science Consultant
Dr. Zhu graduated from Nankai University, China, in 1998 with his BA in Microbiology. After obtaining his MS in Molecular Biology at Institute of Microbiology, Chinese Academy of Science, he went to the U.S. to pursue his PhD in immunology at the Mayo Clinic, which he received in 2006. Dr. Zhu did his postdoctoral training and worked as a research faculty member in Dr. Lieping Chen’s laboratory at Johns Hopkins University and Yale University. Currently Dr. Zhu is an assistant professor in the Department of Surgery at the University of Colorado Anschutz Medical Campus. His research focuses on the discovery of novel immunomodulatory pathways and their potential applications in cancer immunotherapy. He brings his expertise in immunology to the project and services as a leading scientific consultant in Immunoah Therapeutics, Inc.
Immunoah Therapeutics, Inc. is a biotech startup company focusing on the discovery, development, and commercialization of novel therapeutic monoclonal antibodies and their applications in cancer immunotherapies. Our lead product candidate, Zymwolumab, is a group of proprietary agonist antibodies, which demonstrated potent immunological enhancement and anticancer effects. A PCT filing was completed and its right in the region of China was licensed out to a pharmaceutical company in 2017.
Min Wang, MD
Founder and Chairman
Dr. Wang graduated from Beijing Medical University, received his postdoctorate research fellowship training in immunology from Washington University School of Medicine in St. Louis, and received his resident physician training from the University of Minnesota School of Medicine. He holds medical licenses in California and Colorado with clinical expertise in anesthesiology, pain medicine and critical care. Dr. Wang is also the founders of several biotech startups, including Beijing ATGC Gene Tech Corp, one of the leading clinical diagnostic companies providing services in personalized medicine. He serves as Chief Medical Officer in Shanghai Syndegen Biotechnology Co. and Quintara Discovery.
Libin Shi, MD, PhD
Director of Research
Dr. Libin Shi earned her PhD in Biochemistry and Molecular Biology after graduated with Master degree in Medical Microbiology from Dalian Medical University. She also had her M.D. from the same university. She did her postdoctoral training and then worked as a Research Scientist at Colorado State University. Her previous research was focused on developing novel biomarkers for tuberculosis diagnosis and identification of mycobacterial drug targets. Dr. Shi played a critical leadership role in daily laboratory research after she joined Immunoah Therapeutics, Inc. as a Director of Research.